Yuncheng Man1, Erdem Kucukal1, Ran An1, Allison Bode1,2, Jane A Little3, Umut A Gurkan1,4. 1. Department of Mechanical and Aerospace Engineering, Case Western Reserve University, Cleveland, OH, USA. 2. Division of Hematology and Oncology, School of Medicine, Case Western Reserve University, Cleveland, OH, USA. 3. Division of Hematology and Oncology, Department of Medicine, UNC Blood Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. 4. Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, USA.
Abstract
OBJECTIVES: We present a standardized in vitro microfluidic assay and Occlusion Index (OI) for the assessment of red blood cell (RBC)-mediated microcapillary occlusion and its clinical associations in sickle cell disease (SCD). METHODS: Red blood cell mediated microcapillary occlusion represented by OI and its clinical associations were assessed for seven subjects with hemoglobin-SC disease (HbSC), 18 subjects with homozygous SCD (HbSS), and five control individuals (HbAA). RESULTS: We identified two sub-populations with HbSS based on the OI distribution. HbSS subjects with relatively higher OIs had significantly lower hemoglobin levels, lower fetal hemoglobin (HbF) levels, and lower mean corpuscular volume (MCV), but significantly higher serum lactate dehydrogenase levels and absolute reticulocyte counts, compared to subjects with HbSS and lower OIs. HbSS subjects who had relatively higher OIs were more likely to have had a concomitant diagnosis of intrapulmonary shunting (IPS). Further, lower OI associated with hydroxyurea (HU) responsiveness in subjects with HbSS, as evidenced by significantly elevated HbF levels and MCV. CONCLUSIONS: We demonstrated that RBC-mediated microcapillary occlusion and OI associated with subject clinical phenotype and HU responsiveness in SCD. The presented standardized microfluidic assay may be useful for evaluating clinical phenotype and assessing therapeutic outcomes in SCD, including emerging targeted and curative treatments that aim to improve RBC deformability and microcirculatory health.
OBJECTIVES: We present a standardized in vitro microfluidic assay and Occlusion Index (OI) for the assessment of red blood cell (RBC)-mediated microcapillary occlusion and its clinical associations in sickle cell disease (SCD). METHODS: Red blood cell mediated microcapillary occlusion represented by OI and its clinical associations were assessed for seven subjects with hemoglobin-SC disease (HbSC), 18 subjects with homozygous SCD (HbSS), and five control individuals (HbAA). RESULTS: We identified two sub-populations with HbSS based on the OI distribution. HbSS subjects with relatively higher OIs had significantly lower hemoglobin levels, lower fetal hemoglobin (HbF) levels, and lower mean corpuscular volume (MCV), but significantly higher serum lactate dehydrogenase levels and absolute reticulocyte counts, compared to subjects with HbSS and lower OIs. HbSS subjects who had relatively higher OIs were more likely to have had a concomitant diagnosis of intrapulmonary shunting (IPS). Further, lower OI associated with hydroxyurea (HU) responsiveness in subjects with HbSS, as evidenced by significantly elevated HbF levels and MCV. CONCLUSIONS: We demonstrated that RBC-mediated microcapillary occlusion and OI associated with subject clinical phenotype and HU responsiveness in SCD. The presented standardized microfluidic assay may be useful for evaluating clinical phenotype and assessing therapeutic outcomes in SCD, including emerging targeted and curative treatments that aim to improve RBC deformability and microcirculatory health.
Authors: Idowu Akinsheye; Abdulrahman Alsultan; Nadia Solovieff; Duyen Ngo; Clinton T Baldwin; Paola Sebastiani; David H K Chui; Martin H Steinberg Journal: Blood Date: 2011-04-13 Impact factor: 22.113
Authors: Maria Alejandra Lizarralde Iragorri; Sara El Hoss; Valentine Brousse; Sophie D Lefevre; Michael Dussiot; Tieying Xu; Alexander Rodrigo Ferreira; Yann Lamarre; Ana Cristina Silva Pinto; Simone Kashima; Claudine Lapouméroulie; Dimas Tadeu Covas; Caroline Le Van Kim; Yves Colin; Jacques Elion; Olivier Français; Bruno Le Pioufle; Wassim El Nemer Journal: Lab Chip Date: 2018-09-26 Impact factor: 6.799
Authors: T Alexy; S Sangkatumvong; P Connes; E Pais; J Tripette; J C Barthelemy; T C Fisher; H J Meiselman; M C Khoo; T D Coates Journal: Clin Hemorheol Microcirc Date: 2010 Impact factor: 2.375
Authors: Deepika S Darbari; Onyinye Onyekwere; Mehdi Nouraie; Caterina P Minniti; Lori Luchtman-Jones; Sohail Rana; Craig Sable; Gregory Ensing; Niti Dham; Andrew Campbell; Manuel Arteta; Mark T Gladwin; Oswaldo Castro; James G Taylor; Gregory J Kato; Victor Gordeuk Journal: J Pediatr Date: 2011-09-03 Impact factor: 4.406
Authors: Payal C Desai; Julia E Brittain; Susan K Jones; Adam McDonald; Douglas R Wilson; Rosalie Dominik; Nigel S Key; Leslie V Parise; Kenneth I Ataga Journal: Thromb Res Date: 2013-08-08 Impact factor: 3.944
Authors: Rick Huisjes; Anna Bogdanova; Wouter W van Solinge; Raymond M Schiffelers; Lars Kaestner; Richard van Wijk Journal: Front Physiol Date: 2018-06-01 Impact factor: 4.566
Authors: Yuncheng Man; Debnath Maji; Ran An; Sanjay P Ahuja; Jane A Little; Michael A Suster; Pedram Mohseni; Umut A Gurkan Journal: Lab Chip Date: 2021-03-05 Impact factor: 6.799
Authors: Muhammad Noman Hasan; Ran An; Asya Akkus; Derya Akkaynak; Adrienne R Minerick; Chirag R Kharangate; Umut A Gurkan Journal: Micromachines (Basel) Date: 2021-11-22 Impact factor: 2.891